RECENTLY ADDED
ASAM 49th Annual Conference - Innovations in Addiction Medicine and Science - 2018 (64.5 CME)
Contains 49 Product(s)The nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine.
The ASAM 49th Annual Conference is the nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine. The 2018 program includes more education offerings such as; seven concurrent sessions offerings at a time instead of six, three pre-conference courses instead of two. There will also be three Plenary Sessions that include the popular Opening Plenary Session and Policy Plenary Session and new this year the National Perspectives Plenary Session moderated by the ASAM president with leaders from national federal agencies. There will be other exciting changes to provide learning in a more interactive, casual and fun environment.
Learning Objectives:
At the conclusion of the conference, participants should be able to:
- Identify and describe the new developments affecting the science, policy, and clinical practice of addiction medicine.
- Compare presented clinical guidelines/best practices with the participant's current practice and identify strengths or gaps.
- Analyze new research and science to develop practical applications for treatment or further research.
- Explain recent or upcoming policy changes and identify implications or areas for provider involvement.
- Create a network of professionals or a set of resources that can be used to support the participant's practice.
Accreditation Council for Continuing Medical Education (ACCME)
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The ASAM 49th Annual Conference - Innovations in Addiction Medicine and Science
The American Society of Addiction Medicine designates this enduring material for a maximum of 64.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABAM Transitional Maintenance of Certification (Tmoc)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 64.5 AMA PRA Category 1 Credit(s)™ for completing the The ASAM 48th Annual Conference – Innovations in Addiction Medicine and Science.
American Psychological Association (APA)
The American Society of Addiction Medicine (ASAM) Continuing Medical Education (CME) has been approved for renewal of certification by the APA College of Professional Psychology. ASAM CME credits may be applied toward the APA’s “Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders.”
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
CME Committee Members
- Catherine Friedman, MD, FASAM, Chair
- R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM
- Adam J. Gordon, MD, MPH, FACP, DFASAM
- Zwaantje Hamming, FNP-C, CARN-AP
- Noel Ilogu, MD, MRCP, FASAM
- Herbert L. Malinoff, MD, FACP, DFASAM
- Edwin A. Salsitz, MD, DFASAM
Staff - Sandy Metcalfe; Arlene Deverman, MA, CAE, CFRE; Marica Jackson, PhD
CME Committee, Program Planning Committee and Faculty Disclosure Information
In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These polices include resolving all conflicts of interest between the CME Committee, planning committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
Who Should Attend:
- Physicians and Clinicians
- Researchers and Academics
- Counselors and Students
- Other Health Care Professionals
dedicated to increasing access and improving the quality of addiction treatment and care.
From Overdose to Engagement: Working with First Responders and Emergency Departments (1 CME)
Contains 4 Component(s), Medical Credits OfferedEarn 1 AMA PRA Category 1 Credit(s)™ while learning how professionals in Indiana's Project POINT have been removing as many barriers as possible to help patients get the services they desire, as well as, getting and then, maintaining engagement in treatment, from this conference recording at The ASAM 49th Annual Conference (2018).
(1.0 CME) In this conference recording from the 2018 Annual Conference, you will learn about how emergency department (ED) visits for opioid overdose have increased dramatically over the last several years, mirroring trends in overdose related mortality (1). In Indianapolis alone, our ambulance service—Indianapolis Emergency Medical Services—responded to over 2,000 opioid overdoses in 2016 and are on track to outpace that in 2017. Many local public health and safety agencies have championed increased access to naloxone and participated in trainings making it more widely available and accepted by first responders and community members (2). In Indianapolis, we created project POINT to help link those surviving an opioid overdose with the highest quality emergency care including warm hand offs to on-going treatment. Methods: We convened a group of experts and key stakeholders in our hospital system/community and undertook a quality improvement process to improve the care of overdose survivors while in the ED and through their transition to longitudinal care. Results: We developed a set of core ED services and a plan to implement each of them. Core ED services included: 1) brief assessment by a specialty trained outreach team member (ideally a recovery coach), 2) rapid HIV/hepatitis C testing, 3) naloxone teaching and provision, 3) harm reduction counseling, 4) referral to appropriate next level of care and 5) rapid ED follow up focused on recovery support, increasing/supporting motivation and overcoming logistical barriers. We also created a network of providers who were willing and able to accept our referrals and worked with them to optimize the referral process.
Conclusions: With the growing opioid epidemic, EDs and EMS systems are looking for novel and effective ways to reduce mortality and help bridge patients into recovery. EDs and EMS systems are used to working at all hours, in austere conditions with complex and often critically ill patients. We offer an expansive and largely untapped network of providers which could be brought to bear on this epidemic. Project POINT is one example of how the ED can help drive incremental change—even in areas of the country where access to high quality MAT is limited.
Melissa A. Reyes
MA, CRC
Melissa Reyes, M.A., CRCMelissa Reyes completed her B.A. in Criminal Justice and Criminology at Ball State University in Muncie, IN. Following graduation, she worked as a case manager for the Madison Co. Problem Solving Courts for two years and was involved with both the Drug Court and Mental Health Court. In 2014, she then pursued her M.A. degree at Michigan State University in Rehabilitation Counseling. Melissa transitioned back to her home state of IN with the acceptance of a care coordinator position with Midtown Adult Addictions in Indianapolis, IN in September of 2016. The position was the forerunner of its kind for both organizations, and required constructing a unique collaboration between the community mental health center and Eskenazi Health ED; the area’s safety-net hospital. By January 2017, Melissa had accepted the role of Program Director for Project POINT (Planned Outreach,Intervention, Naloxone, and Treatment). Initially, POINT focused exclusively on providing referrals with warm handoffs, but Melissa expanded the scope and pursued a more holistic approach. This included promoting the start of implementing harm reduction counseling, rapid HIV/HCV testing as well as take home naloxone kits. In March of 2017, POINT expanded to include peer recovery coaching, and Melissa not only oversees the implementation of this new role, but also develops the training and supervision plan. Most recently, in January 2018, Melissa was offered and accepted the position of Project Director, Project POINT and Mobile Project POINT.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Treating Youth with Opioid Addiction: Cases and Controversies (1.5 CME)
Contains 4 Component(s), Medical Credits OfferedEarn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to treat youth with opioid addiction while employing developmentally specific approaches, using relapse prevention medication (MAT), from this conference recording from The ASAM 49th Annual Conference (2018).. The session also includes when and how to involve families, as well as a discussion on issues in confidentiality and the use of various levels of care.
(1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn about more about treating youth with opioid addiction through cases and controversies. Young people are disproportionately affected by the current opioid epidemic, with catastrophic consequences for youth and their families. Despite the urgent need, there is a lack of consensus about treatment approaches for youth. Many practitioners have questions, and struggle with this “mysterious” and difficult to engage population. This workshop will feature an interactive, case-based format. Workshop leaders will present 4-5 cases with background and treatment course, each punctuated by “what would you do next…” management questions for guided discussion at several pivotal decision points in the course. Cases are chosen to reflect real world concerns and clinical conundrums, key learning objectives, practice debates and controversies.
The goal is to engage participants in a lively conversation about developmentally-informed strategies, approaches, and treatment options in the treatment of this critical target population.
Featured cases
- 18 M at 5th episode of residential detoxification who has been unable to sustain continuing outpatient care despite previous course of buprenorphine.
- 19 F who becomes pregnant during treatment with extended release naltrexone.
- 20 M in outpatient treatment, abstinent from opioids on buprenorphine, but struggling with cocaine and other non-opioid substances, opposes communication with family.
- 17 F who presents in crisis to residential treatment seeking detoxification, and struggles with the process of decision making around recommendations for and choice of relapse prevention medications (buprenorphine vs extended release naltrexone).
- 18 M with sickle cell anemia with repeated relapses despite multiple treatment levels of care, including multiple attempts at outpatient buprenorphine treatment under various programmatic conditions.
The case discussions will cover a range of questions, including:
- developmentally specific approaches to treatment of adolescents and young adults with OUDs;
- use of relapse prevention medication (MAT) in youth;
- the role of families, when and how to involve them;
- confidentiality; use of various levels of care;
- the impact of other substance use disorders (primarily cannabis and alcohol);
- delivery models for medications and psychosocial treatment modalities; and others.
Marc Fishman
MD, DFASAM
Marc Fishman MD is a specialist in addiction psychiatry and addiction medicine. He is a member of the faculty of the Department of Psychiatry at the Johns Hopkins University School of Medicine. He leads Maryland Treatment Centers, which offers programs for residential and outpatient treatment of drug-involved and dual-diagnosis adolescents and adults. He has written and lectured widely on a variety of topics including youth treatment, placement and treatment matching strategies, co-occurring disorders, and medication treatment for addiction. His research focus has been in treatment of opioid use disorders in youth.
Dr. Fishman served as a co-editor for the most recent editions of ASAM's Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine, and also a current member of the Board.
Bikash Sharma
MD
Bikash Sharma, MD is currently a medical director for adult services at the Mountain Manor Baltimore, Maryland Treatment Centers. Dr. Sharma has board certifications with the American Board of Psychiatry and Neurology as well as the American Board of Addiction Psychiatry. He has been published in numerous journals where he has written about opioid use disorders, and alcohol and substance use in African Americans.
Ann Bruner
MD
Ann Bruner, MD is a Medical Director, who treats youth at the Mountain Manor Baltimore, Maryland Treatment Centers. Dr. Bruner is referenced as an author or co-author in dozens of peer-reviewed journals in the Journal of Adolescent Health, and a contributor to the Clinical Handbook of Adolescent Addiction.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Webinar: Addiction Medicine: The Next Generation (1 CME)
Contains 4 Component(s), Medical Credits OfferedThis webinar will cover what an addiction medicine specialist looks like, the different settings an addiction medicine clinician can work in, and the future pathways physician will have to become board-certified in Addiction Medicine.
This on-demand webinar will cover what an addiction medicine specialist looks like, the different settings an addiction medicine clinician can work in, and the future pathway physician have to become ADM certified.
This webinar is ideal for pre-medical student, medical students, residents, and medical school administrators.
Upon completion of this activity, participants will be able to:
- Explain recent updates to the Addiction Medicine field.
- Describe how changes to the certification process further integrate addiction treatment into the health care system.
- Appraise which pathways they are eligible to the ABPM ADM exam.
- Define the different pathways a physician can take from to the ABPM exam.
- Identify the need for more physicians to become board-certified in addiction medicine.
- Explain the basic components of an addiction medicine specialist.
Louis E. Baxter, Sr.
MD, DFASAM
Dr. Louis E. Baxter, Sr., MD, DFASAM is a Past ASAM President and is the President &CEO of thr Professional Assistance Program of New Jersey, Inc.
Dr. Baxter is a certified in Addiction Medicine by the American Board of Addiction Medicine and formerly served on the Board of Directors. Dr. Baxter has served and chaired many government advisory committees and panels which include SAMHSA, NIDA, CSAT, NIAAA, and a Presidential Advisor through ONDCP since the Clinton Administration.
Dr. Baxter has served the State of New Jersey in various capacities serving on the Governor's Council for Drug and Alcohol Addiction, Medical Director for the Division of Addiction Services, and most recently as the Addiction Medicine Consultant for the Division of Mental Health and Addiction Services. He has held academic appointments as Assistant Clinical Professor of Medicine for former University Medicine & Dentistry and now currently with Rutgers New Jersey Medical School in Newark, NJ. Dr. Baxter is serving as Co-Director if the Addiction Medicine Fellowship Program at Howard University Medical School and Hospital.
Helen E. Jack
MD
Helen Jack is a fourth year student at Harvard Medical School. In medical school, her research has focused on how lay health workers, including recovery coaches and community health workers, can contribute to care access and outcomes. She also helps organize the Student Coalition on Addiction, a group of medical students from across Massachusetts engaged in advocacy on addiction medicine education and access to treatment services. She holds a Visiting Researcher position at the Institute of Psychology, Psychiatry, and Neuroscience at King's College London. With KCL, she conducts mental health systems research in Zimbabwe and works on a Wellcome Trust-funded project to build mental health research capacity in southern Africa. Helen graduated from Yale University in 2012. Following graduation, she got a second BA in Philosophy, Politics, and Economics at Oxford University as a Rhodes Scholar.
Anna Lembke
MD, FASAM
Dr. Anna Lembke is currently an Associate Professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine. She is a diplomate of the American Board of Psychiatry and Neurology, a diplomate of the American Board of Addiction Medicine, the Program Director for the Stanford University Addiction Medicine Fellowship, and Chief of the Stanford Addiction Medicine Dual Diagnosis Clinic.
She has published peer-reviewed articles, chapters, and commentaries, including in the New England Journal of Medicine, the Journal of the American Medical Association, the Journal of General Internal Medicine, and Addiction. Dr. Lembke sees patients, teaches, and does research. She is the author of a book on the prescription drug epidemic: “Drug Dealer, MD: How Doctors Were Duped, Patients Got Hooked, and Why It’s So Hard to Stop” (Johns Hopkins University Press, October 2016).
Addiction Medicine: The Next Generation Webinar Planning Committee
Name
Disclosure
Peter L. Selby MBBS, CCFP, FCFP, MHSc, DFASAM
Johnson and Johnson: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support;Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO
No Financial Relationships or Conflicts of Interest
Mark P. Schwartz, MD, FAAFP, DFASAM No Financial Relationships or Conflicts of Interest Louis E. Baxter, MD, DFASAM No Financial Relationships or Conflicts of Interest Helen Jack No Financial Relationships or Conflicts of Interest Anna Lembke, MD, FASAM No Financial Relationships or Conflicts of Interest ASAM CME Committee
Name
Disclosure
Catherine Friedman, MD, FAPA, FASAM, Chair
No Financial Relationships or Conflicts of Interest
Adam J. Gordon, MD, MPH, FACP, DFASAM
No Financial Relationships or Conflicts of Interest
Noel Ilogu, MD, MRCP, DFASAM
No Financial Relationships or Conflicts of Interest
Herbert L. Malinoff, MD, FACP, DFASAM
No Financial Relationships or Conflicts of Interest
Edwin A. Salsitz, MD, DFASAM
No Financial Relationships or Conflicts of Interest
John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO
Indivior, Honorarium, Speaker; BDSI, Honorarium, Consultant/SpeakerCommercial Interest Definition
A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Webinar: Pathways to the Addiction Medicine Subspecialty (1 CME)
Contains 4 Component(s), Medical Credits OfferedThis webinar will begin with an overview of the current state of the addiction epidemic, then move onto other topics including the gap in addiction treatment, the role physicians can play to help close the gap, and the importance, as well as how to apply for the ADM exam. Earn 1 CME while learning how to become board-certified in Addiction Medicine.
This on-demand webinar will begin with an overview of the current state of the addiction epidemic and the huge gap in addiction treatment. It will then move on to the role physicians can play to help close this gap, and the importance to sit for the ABPM Addiction Medicine exam. The webinar will then move on to a representative from ABPM discussing the details of how physicians can apply for the ADM exam and any “lessons learned” from last year.
This webinar is ideal for any physician interested in addiction medicine, ABAM Diplomates, DATA 2000 waivered physicians, medical directors, and others.
Upon completion of this activity, participants will be able to:
- Explain recent updates to the Addiction Medicine field.
- Describe how changes to the certification process further integrate addiction treatment into the health care system.
- Appraise which pathways they are eligible to the ABPM ADM exam.
- Define the different pathways a physician can take from to the ABPM exam.
- Identify the need for more physicians to become board-certified in addiction medicine.
Shawn A. Ryan
MD, MBA, FASAM
Shawn A. Ryan, MD, MBA is an Dual Board Certified Emergency Physician as well as Addiction Specialist. He is currently an assistant professor, Department of Emergency Medicine, University of Cincinnati, and President & CMO of BrightView Health. Dr. Ryan is currently practicing addiction medicine treatment in Cincinnati, is published on this issue, and also serves on many regional, state, and national committees addressing this complicated subject. Dr. Ryan is President of the Ohio Society of Addiction Medicine and the Chair of Payer-Relations for ASAM and he spends a significant amount of time working with large commercial payers and Medicaid administrators on current and future payment strategies.
Steven Daviss
MD, DFAPA
Steven Daviss, MD, DFAPA is a physician, double-boarded in Psychiatry and in Psychosomatic Medicine, which is the intersection of primary care and psychiatry. He is currently a senior medical advisor for the Office of the CMO at SAMSHA. He is the past Chair of the Department of Psychiatry at Baltimore Washington Medical Center (2004-2014), and is a Clinical Assistant Professor in the University of Maryland School of Medicine, where he also attended medical school. He trained at the University of Pittsburgh Medical Center at Western Psychiatric Institute and Clinic. He completed an NIMH-funded clinical research fellowship in schizophrenia at the Maryland Psychiatric Research Center.
Michael F. Weaver
MD, DFASAM
Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine. He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.
Pathways to the Addiction Medicine Subspecialty Webinar Planning Committee
Name
Disclosure
Peter L. Selby MBBS, CCFP, FCFP, MHSc, DFASAM
Johnson and Johnson: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support;Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment
Adam J. Gordon, MD, MPH, FACP, DFASAM
No Financial Relationships or Conflicts of Interest
Mark P. Schwartz, MD, FAAFP, DFASAM No Financial Relationships or Conflicts of Interest Shawn Ryan, MD, MBA, FASAM Adapt & Braeburn: Consultant Steven Daviss, MD, DFAPA No Financial Relationships or Conflicts of Interest Michael Weaver, MD, DFASAM No Financial Relationships or Conflicts of Interest ASAM CME Committee
Name
Disclosure
Catherine Friedman, MD, FAPA, FASAM, Chair
No Financial Relationships or Conflicts of Interest
Adam J. Gordon, MD, MPH, FACP, DFASAM
No Financial Relationships or Conflicts of Interest
Noel Ilogu, MD, MRCP, DFASAM
No Financial Relationships or Conflicts of Interest
Herbert L. Malinoff, MD, FACP, DFASAM
No Financial Relationships or Conflicts of Interest
Edwin A. Salsitz, MD, DFASAM
No Financial Relationships or Conflicts of Interest
John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO
Indivior, Honorarium, Speaker; BDSI, Honorarium, Consultant/SpeakerCommercial Interest Definition
A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
